NCT02875223 2025-04-20
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Celgene
Phase 1 Terminated
Celgene
AstraZeneca
GlaxoSmithKline
Eisai Inc.
Jiangsu HengRui Medicine Co., Ltd.
AstraZeneca
Hoffmann-La Roche
Bayer
Seagen Inc.
AbbVie